SRRKScholar Rock Holding Corporation
Price
+37%1YEnd-of-day closes, not the intraday tick.
More going right than wrong
Quality strong, nothing alarming, the market undecided.
We are a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (“SMA”) and additional rare, severe and debilitating neuromuscular diseases. As a leader in the biology of the transforming growth factor beta (“TGFβ”) superfamily, our novel understanding of the molecular mechanisms of growth factor activation enabled the development of a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors.
In the company’s own words · 10-K filed Mar 3, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Scholar Rock Holding Corporation (SRRK) reported revenue of $0 in Q2 2026 (quarter ended Jun 30, 2026). That came with net loss of $110M. For the full year FY2025, revenue was $0 and net income −$378M. The next results filing is expected around Nov 13, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 14, 2026On September 11, 2026, the Company announced that the FDA has approved ISEMBYLD™ (apitegromab-mstn) for the treatment of SMA in adults and children 2 years of age and older who are currently receiving a survival SMN2 targeted treatment.Regulation FD disclosure · Form 8-K
- Aug 6, 2026Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights.Earnings release · press release
- Aug 6, 2026As previously disclosed, Scholar Rock Holding Corporation (the “Company”) entered into an Open Market Sale Agreement SM, dated November 14, 2022, with Jefferies LLC (“Jefferies”) relating to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares …Other event · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.